Do investors value the FDA orphan drug designation?

類似資料

• Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
  著者:: Miller, Kathleen L., 等
  出版事項: (2021)
• FDA orphan drug designations for lysosomal storage disorders – a cross-sectional analysis
  著者:: Garbade, Sven F., 等
  出版事項: (2020)
• The drug development pipeline for glioblastoma—A cross sectional assessment of the FDA Orphan Drug Product designation database
  著者:: Johann, Pascal, 等
  出版事項: (2021)
• Precision Medicines’ Impact on Orphan Drug Designation
  著者:: Mueller, Christine M., 等
  出版事項: (2019)
• The Push for Additional Orphan Drugs: Can the FDA Do More to Encourage Their Development?
  著者:: Barlas, Stephen
  出版事項: (2016)